IceCure Medical (ICCM) Stock Price, News & Analysis

Company Overview

IceCure Medical Ltd. (NASDAQ: ICCM) is a clinical-stage medical device company specializing in the development and commercialization of proprietary cryoablation systems for the treatment of tumors and other pathological tissues. The company’s core technology employs a unique liquid-nitrogen-based platform to deliver rapid cooling through fine-gauge cryoprobes, enabling precise and minimally invasive tissue ablation under imaging guidance. IceCure’s lead product, ProSense, is designed to offer a single-probe approach that can be deployed in an outpatient setting, reducing procedure time and patient recovery periods.

Originally founded in Israel, IceCure Medical obtained its first CE mark for the treatment of benign breast tumors and fibroadenomas in 2017. Since then, the company has expanded ProSense’s indications to include treatment of various soft-tissue lesions and small renal tumors. IceCure continues to pursue regulatory approvals in multiple jurisdictions, leveraging partnerships with distributors and clinical research organizations to support both commercial launches and ongoing clinical trials.

With its headquarters located in Caesarea, Israel, IceCure Medical maintains a presence in Europe and Latin America and is actively engaged in preparatory work for entry into the U.S. market. The company has submitted an IDE application with the U.S. Food and Drug Administration to initiate pivotal studies assessing ProSense’s safety and efficacy in the treatment of malignant lesions in the breast. IceCure’s commercial strategy focuses on penetrating high-volume oncology and interventional radiology centers, as well as expanding its footprint through strategic collaborations.

Under the leadership of an experienced management team with deep expertise in interventional oncology and medical device commercialization, IceCure Medical continues to advance its platform through product enhancements and new clinical applications. The company’s ongoing research efforts aim to broaden the utility of its cryoablation technology to address additional indications, underscoring its commitment to offering minimally invasive therapeutic options for cancer and other serious diseases.

Key Stats

• Today's Range: $2.31 to $2.50
• 50-Day Range: $2.13 to $9.30
• 52-Week Range: $2.12 to $42.00
• Volume: 107,205 shs
• Average Volume: 126,880 shs
• Market Capitalization: $8.33 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $52.50
• Consensus Rating: Hold

IceCure Medical Stock Analysis - MarketRank™

IceCure Medical scored higher than 57% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Hold

Consensus Rating

IceCure Medical has received a consensus rating of Hold. The company's average rating score is 2.20, and is based on no strong buy ratings, 3 buy ratings, no hold ratings, and 2 sell ratings.

Upside Potential

IceCure Medical has a consensus price target of $52.50, representing about 2,060.5% upside from its current price of $2.43.

Amount of Analyst Coverage

IceCure Medical has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for IceCure Medical are expected to grow in the coming year, from ($4.61) to ($3.61) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of IceCure Medical is -0.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of IceCure Medical is -0.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

IceCure Medical has a P/B Ratio of 0.70. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.12% of the float of IceCure Medical has been sold short.

Short Interest Ratio / Days to Cover

IceCure Medical has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in IceCure Medical has recently decreased by 66.28%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

IceCure Medical does not currently pay a dividend.

Dividend Growth

IceCure Medical does not have a long track record of dividend growth.

News and Social Media

• Score: 0.8 / 5
• News Sentiment: -0.64

News Sentiment

IceCure Medical has a news sentiment score of -0.64. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.61 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 11 news articles for IceCure Medical this week, compared to 3 articles on an average week.

Search Interest

Only 1 people have searched for ICCM on MarketBeat in the last 30 days. This is a decrease of -86% compared to the previous 30 days.

Company Ownership

• Score: 0.1 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, IceCure Medical insiders have not sold or bought any company stock.

Percentage Held by Insiders

2.44% of the stock of IceCure Medical is held by insiders.

Percentage Held by Institutions

0.62% of the stock of IceCure Medical is held by institutions.

Company Calendar

• Last Earnings: 6/30/2026
• Today: 8/21/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Healthcare Equipment & Supplies
• Sub-Industry: Healthcare Equipment
• Current Symbol: NASDAQ:ICCM
• CIK: 1584371
• Web: www.icecure-medical.com
• Phone: 972-4623-0333
• Fax: 972-4623-0222
• Employees: 60
• Year Founded: 2006

Price Target and Rating

• Average Price Target for IceCure Medical: $52.50
• High Price Target: $75.00
• Low Price Target: $30.00
• Potential Upside/Downside: +2,060.5%
• Consensus Rating: Hold
• Rating Score (0-4): 2.20
• Research Coverage: 5 Analysts

Profitability

• EPS (Trailing Twelve Months): ($8.52)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$15.06 million
• Net Margins: -427.67%
• Pretax Margin: -445.61%
• Return on Equity: -174.26%
• Return on Assets: -112.58%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.88
• Quick Ratio: 2.44

Sales & Book Value

• Annual Sales: $3.95 million
• Price / Sales: 2.11
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $3.47 per share
• Price / Book: 0.70

Miscellaneous

• Outstanding Shares: 3,426,000
• Free Float: 3,342,000
• Market Cap: $8.33 million
• Optionable: Not Optionable
• Beta: 0.47